

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-21. (Canceled)

22. (Currently Amended) A recombinant Fel d 1 fusion product comprising a Fel d 1 chain 1 ~~[[,]]~~ and a Fel d 1 chain 2, wherein the Fel d 1 chain 1 comprises the amino acid sequence set forth in SEQ ID NO: 1 or a variant ~~thereof~~ of the amino acid sequence set forth in SEQ ID NO: 1, wherein Fel d 1 chain 2 comprises (i) the amino acid sequence set forth in SEQ ID NO: 2 or a variant ~~thereof~~ of the amino acid sequence set forth in SEQ ID NO: 2 or (ii) the amino acid sequence set forth in SEQ ID NO: 3, wherein the N-terminus of the Fel d 1 chain 1 is in peptide linkage with the C-terminus of the Fel d 1 chain 2, wherein the variant of the amino acid sequence set forth in SEQ ID NO:1 is selected from the group consisting of SEQ ID NO: 1 having Lys29Arg, SEQ ID NO: 1 having Lys 29Asn and SEQ ID NO: 1 having Val33Ser, and wherein the variant of the amino acid sequence set forth in SEQ ID NO:2 is selected from the group consisting of SEQ ID NO:2 having Asn19Ser, SEQ ID NO:2 having Gly20 Leu, ~~ile55Val~~ SEQ ID NO:2 having Ile55Val, SEQ ID NO:2 having Arg57Lys, SEQ ID NO:2 having Val58Phe, SEQ ID NO:2 having Glu69Val, SEQ ID NO:2 having Tyr72Asp, SEQ ID NO:2 having Gln79Glu and SEQ ID NO:2 having Asn88Lys.

23. (Canceled)

24. (Canceled)

25. (Canceled)

26. (Canceled)

27. (Canceled)

28. (Previously presented) A fusion product as claimed in claim 22, wherein the chain 1 and the chain 2 are covalently bonded together by one or more disulfide bridges into an antiparallel arrangement.

29. (Canceled)

30. (Canceled)

31. (Canceled)

32. (Canceled)

33. (Previously presented) A homodimer consisting of two non-covalently associated fusion products as claimed in claim 22.

34. (Withdrawn) A DNA sequence encoding the fusion product as claimed in claim 22.

35. (Withdrawn) An expression vector having the DNA sequence as claimed in claim 34 inserted therein in an operable form.

36. (Withdrawn) A host cell transformed with the expression vector as claimed in claim 35.

37. (Previously presented) A pharmaceutical composition comprising an immunotherapeutically effective amount of the fusion product as claimed in claim 22 and/or the homodimer as claimed in claim 33 and a pharmaceutically acceptable carrier, excipient or diluent.

38. (Previously presented) A kit for the diagnosis of cat allergy comprising the fusion product as claimed in claim 22 and/or the homodimer as claimed in claim 33 and instructions for use of the kit.

39. (Withdrawn) A method for diagnosing cat allergy comprising the step of combining a sample taken from a subject with the fusion product as claimed in claim 22, the homodimer as claimed in claim 33, or a combination thereof.

40. (Withdrawn) A process for preparing a fusion product as claimed in claim 22 comprising the step of culturing the host cell as claimed in claim 36 in a suitable medium.

41. (Canceled)

42. (Previously Presented) The fusion product of claim 22, wherein the Fel d 1 chain 2 further has a methionine residue on the N-terminus.

43. (Previously Presented) The fusion product of claim 22, wherein the Fel d 1 chain 1 further has the sequence Leu-Glu-(His)₆ on the C-terminus.

44. (Previously Presented) The fusion product of claim 42, wherein the Fel d 1 chain 1 further has the sequence Leu-Glu-(His)₆ on the C-terminus.

45. (Previously Presented) The fusion product of claim 44, wherein the fusion product has the amino acid sequence set forth in SEQ ID NO: 4.

46. (Previously Presented) A pharmaceutical composition comprising an immunotherapeutically effective amount of the fusion product as claimed in claim 45 and a pharmaceutically acceptable carrier, excipient or diluent.

47. (Previously Presented) A kit for the diagnosis of cat allergy comprising the fusion product as claimed in claim 45 and instructions for use of the kit.